Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) is an important modulator of high density lipoprotein cholesterol in humans and thus considered to be a therapeutic target for preventing cardiovascular disease.
|
15681846 |
2005 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) plays a key role in the metabolism of high-density lipoprotein (HDL), a strong, inverse, independent risk factor for cardiovascular disease.
|
17949364 |
2007 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis.
|
18243217 |
2008 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Cholesteryl ester transfer protein B1B1 genotype is associated with a parental history of cardiovascular diseases in Taiwanese people.
|
18287799 |
2008 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
|
18957472 |
2008 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) plays a major role in lipid metabolism, but studies on the association of CETP polymorphisms with risks of cardiovascular disease are inconsistent.
|
23039379 |
2012 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) I405V polymorphism and cardiovascular disease in eastern European Caucasians - a cross-sectional study.
|
27439317 |
2016 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
CETP (cholesteryl ester transfer protein) plays an important role in lipoprotein metabolism; however, whether inhibition of CETP activity can prevent cardiovascular disease remains controversial.
|
28428219 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) inhibitors are a new class of therapeutics for dyslipidemia that simultaneously improve two major cardiovascular disease (CVD) risk factors: elevated low-density lipoprotein (LDL) cholesterol and decreased high-density lipoprotein (HDL) cholesterol.
|
28911944 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) has been identified as a potential target for cardiovascular disease (CVD) for its important role in the reverse cholesteryl transfer (RCT) process.
|
29112169 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) inhibitor-mediated induction of HDL-cholesterol has no effect on the protection from cardiovascular disease (CVD).
|
31054484 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) belongs to the group of enzymes which inhibition have the application in the treatment of cardiovascular diseases.
|
31215331 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) is an attractive therapeutic target for the prevention and treatment of cardiovascular diseases by lowering low-density lipoprotein cholesterol levels as well as raising high-density lipoprotein cholesterol levels in human plasma.
|
31780304 |
2020 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A cholesteryl ester transfer protein (CETP) genotype (V/V homozygosity for I405V, NCBI dbSNP rs5882) has been associated with preservation of cognitive function in old age, in addition to its associations with exceptional longevity and cardiovascular disease.
|
17531380 |
2007 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A CETP polymorphism improves the diagnostic power of clinical examination in patients with cardiovascular disease.
|
20458649 |
2010 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A lower cholesterol concentration in the HDL fraction in children with a family history of cardiovascular system diseases was determined by polymorphism of the CETP gene.
|
24091356 |
2013 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Because low levels of plasma CETP are associated with increased plasma HDL-cholesterol, therapeutic inhibition of CETP activity is considered an attractive strategy for elevating plasma HDL-cholesterol, thereby hoping to reduce the risk of cardiovascular disease.
|
28767652 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Candidate gene polymorphism in cardiovascular disease: the BIP cohort.
|
16544732 |
2006 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
LHGDN |
CETP levels rather than polymorphisms as markers of coronary risk: healthy athlete with high HDL-C and coronary disease--effectiveness of probucol.
|
16563399 |
2006 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis.
|
18518852 |
2008 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis.
|
18518852 |
2008 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Concomitant presence of both, CETP B1 and NOS3 T allele, associated with increased risk of T2DM, CVD and CVD in T2DM by 8.36-, 6.33- and 7.87-fold, respectively, while concomitant presence of ANGPTL8 variant with either CETP B1 or NOS3 T allele was not associated with increased risk of T2DM or CVD.
|
29973202 |
2018 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Different therapies have been suggested and some are used to treat elevated lipoprotein(a) levels such as niacin, PCSK9 inhibitors, and CETP inhibitors; however, to date, no randomized controlled trial has demonstrated that lowering of lipoprotein(a) leads to lower risk of cardiovascular disease.
|
31111240 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
|
30610681 |
2019 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Efforts to raise HDL level via CETP inhibitors, Torcetrapib and Dalcetrapib, turned out to be disappointing in outcome studies despite substantial increases in HDL-C, suggesting that factors beyond HDL concentration may be responsible for the increased risks of CVD.
|
28828539 |
2018 |